Metabolic Heterogeneity Underlying Hypertriglyceridemia: Hepatic Triglyceride Biosynthesis in Humans With Different Insulin Resistance Phenotypes
Yale University
40 participants
Nov 16, 2023
INTERVENTIONAL
Conditions
Summary
The focus of this cross-sectional study is to determine the effects of tissue-specific (adipose tissue or muscle) vs global (combined) insulin resistance (IR) on hepatic triglyceride biosynthesis in humans, and to determine differential effects of an acute exercise intervention on hepatic triglyceride biosynthesis in these groups.
Eligibility
Inclusion Criteria5
- Ability to give informed consent
- Overweight, defined as BMI 25-30 kg/m2
- Modest hypertriglyceridemia, defined as fasting plasma triglycerides 1.5-3.0mM
- High risk of insulin resistance, defined as fasting plasma insulin \>64pM
- Stable weight for at least 3mo prior to participation
Exclusion Criteria7
- Active or chronic liver disease, kidney disease, congestive heart failure, unstable angina, history of acute cardiovascular events within 6mo of screening, history of seizures or syncope, or an active infection requiring antimicrobial therapy;
- Use of insulin, thiazolidinediones, SGLT2 inhibitors, or sulfonylureas;
- Use of fibrates, omega 3 (fish oil), niacin, or PCSK9 antagonists;
- Use of systemic glucocorticoids within 60d prior to participation;
- Hematocrit \<35%;
- Pregnancy of breastfeeding;
- Active tobacco use, excessive alcohol intake (\>14U/wk), or history of drug abuse.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
De novo lipogenesis (DNL) will be assessed in all participants with a standardized dinner
DNL will be assessed in all participants with short bouts of premeal exercise with a standardized dinner
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05743868